/
We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms.
$6.13
+$0.29 (+4.97%)
EOD Jul 17, 2026
Operating margin is thin at 8.00%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 13.5% YoY with margins expanding 22.7pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$58M
▲ +13.5% YoY
Net Income (TTM)
-$2M
▲ +164.6% YoY
Op. Margin
-4.53%
▲ +22.7pp YoY
ROIC
-21.60%
▲ +105.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$4M
▲ +200.3% YoY
Op. Cash Flow (TTM)
$4M
▲ +220.4% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$7M
5Y CAGR: +12.1%
5Y CAGR: +59.2%
Continue Research
Champions Oncology (CSBR) trades above a two-stage DCF intrinsic value of about $4.92 per share, so at $6.13 the stock looks overvalued (19.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Champions Oncology scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $4.92 per share for CSBR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $3.69. At today's $6.13, that puts the stock about 19.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Champions Oncology scores 38 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -4.5% operating margin and a -21.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CSBR currently trades above its estimated intrinsic value and scores 38/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.